Loading Density Influences the Tumor Cell Targeting and Signaling Inhibition Capabilities of Antibody Nanoconjugates

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
• Nanoparticle-based therapies, specifically antibody-nanoparticle conjugates, show promise for targeted TNBC treatment.
• Frizzled7 (FZD7) antibody-conjugated nanoshells (NS) can target TNBC cells and inhibit Wnt signaling.

Purpose of the Study:

• To investigate the impact of antibody loading density on FZD7-NS conjugate efficacy for TNBC.
• To determine how varying antibody densities affect TNBC cell binding, Wnt signaling suppression, and therapeutic outcomes.

Main Methods:

• Conjugation of Frizzled7 antibodies to silica-gold nanoshells at two densities (approx. 60 and 170 antibodies/NS).
• Evaluation of conjugate binding avidity to MDA-MB-231 TNBC cells using flow cytometry.
• Assessment of Wnt target gene inhibition via RT-qPCR.
• Analysis of tumor spheroid growth, metabolic activity, and cell number after conjugate treatment.

Main Results:

• Lower antibody density (∼60 antibodies/NS) resulted in significantly higher binding avidity to TNBC cells compared to higher density (∼170 antibodies/NS).
• Low-density FZD7-NS demonstrated more effective suppression of Wnt target genes.
• Treatment with low-density FZD7-NS led to a greater reduction in tumor spheroid size, metabolic activity, and cell number.

Conclusions:

• Antibody loading density is a critical factor in the therapeutic efficacy of antibody-nanoparticle conjugates.
• Optimizing surface ligand density is essential for designing effective nanoparticle-based treatments for TNBC.
• These findings provide valuable structure-function insights for developing targeted nanomedicines.